A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

NCT05143463 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurodegenerative Diseases

Interventions

DRUG: NS101 IV infusion

Sponsor

Neuracle Science Co., LTD.